Trails Edge Capital Partners LP Invests $10.13 Billion in Century Therapeutics, Inc. $IPSC

Trails Edge Capital Partners LP acquired a new stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) during the second quarter, HoldingsChannel reports. The firm acquired 4,134,969 shares of the company’s stock, valued at approximately $10,130,674,000. Century Therapeutics accounts for 1.6% of Trails Edge Capital Partners LP’s holdings, making the stock its 25th largest holding.

Other large investors have also modified their holdings of the company. Bank of New York Mellon Corp bought a new position in Century Therapeutics in the first quarter worth $29,000. Quadrant Private Wealth Management LLC boosted its stake in Century Therapeutics by 31.0% during the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock worth $45,000 after buying an additional 4,736 shares in the last quarter. State of Wyoming bought a new stake in Century Therapeutics in the 2nd quarter valued at $82,000. The Manufacturers Life Insurance Company bought a new stake in Century Therapeutics in the 2nd quarter valued at $85,000. Finally, Legal & General Group Plc acquired a new position in shares of Century Therapeutics in the 2nd quarter valued at $108,000. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Finally, Mizuho assumed coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 price target for the company. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $4.75.

Century Therapeutics Price Performance

Shares of NASDAQ:IPSC opened at $2.17 on Wednesday. The business’s fifty day moving average price is $2.17 and its two-hundred day moving average price is $2.22. Century Therapeutics, Inc. has a fifty-two week low of $0.44 and a fifty-two week high of $3.04. The stock has a market capitalization of $392.92 million, a price-to-earnings ratio of -2.33 and a beta of 1.57.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). Research analysts expect that Century Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Century Therapeutics Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.